Peptide nomenclature presents a significant challenge for researchers handling the vast and growing field of biomedical literature, where a single compound can appear under dozens of different names across thousands of articles.
PubMed, the National Library of Medicine’s index of biomedical literature, now holds more than 40 million citations and continues to expand by upward of 1.5 million new articles each year. A single research peptide can appear under half a dozen different names across that literature. A 2025 bibliometric analysis built from PubMed-indexed literature identified 87,611 peptide-related research articles spanning 28 countries and regions.
UniProtKB, the primary reference protein sequence database, held more than 227 million sequence entries as of its 2025 release, with its manually curated Swiss-Prot section alone built from over 312,000 unique literature references. The CAS REGISTRY has logged more than 72 million sequence-based entries for proteins and nucleic acids as part of a broader substance count exceeding 290 million.
Related: Canada’s Indigenous tobacco retail landscape explained
The sequence-derived name describes the peptide by its amino acid chain. The target- or mechanism-derived name labels a peptide according to the biological pathway or receptor it is studied against, and can produce collisions between structurally distinct peptides. Manufacturer or supplier shorthand is an informal but widely used naming layer, rarely codified by any standards body. The numeric or alphanumeric lab code is typically assigned during early-stage development, and sometimes persists in the literature long after a peptide has acquired a more descriptive name.
Systematic names versus common names offer a different kind of distinction. The systematic name is derived from IUPAC chemical nomenclature rules and describes the molecule’s structure unambiguously, following conventions the International Union of Pure and Applied Chemistry and the International Union of Biochemistry and Molecular Biology jointly formalized starting in 1984. The common name is shorter and more usable, but depends entirely on community consensus to remain unambiguous.
For a researcher trying to find all available data on a specific molecule, this fragmentation creates a practical barrier. If you search using only a common name, you retrieve a subset of the relevant literature; the same search run against a systematic name, a numeric code, or an alternate common name can surface a materially different set of results. Meta-analyses and systematic reviews are particularly exposed to this risk, as a single missed alias can skew the entire dataset.
The World Health Organization’s International Nonproprietary Name program assigns a single official name to pharmacologically active substances, though INN assignment is not automatic and many research-stage peptides operate for years without one. Sequence databases provide a second layer of standardization by anchoring names to verifiable structural data, with UniProtKB’s curated entries linking accession numbers to specific sequences and the CAS Registry assigning a unique registry number to each distinct chemical entity.
Related: How to Compare Top Online Meat Delivery Services
The naming layers described above are visible in how research peptide suppliers structure their own catalogs, since supplier listings routinely carry a compound’s common research name alongside its recognized alternate designations. Bluum Peptides catalogs its research compounds this way, listing entries such as BPC-157 and TB-500 under both their established common research names and the alternate codes and designations associated with the same sequences in the literature.
Text-mining and natural language processing tools aimed at biomedical literature are increasingly being applied to the problem of entity resolution, the task of automatically recognizing when two differently named terms refer to the same underlying compound. However, peptide nomenclature is fragmented for structural reasons that are unlikely to resolve on their own. Systematic naming under IUPAC-IUB conventions provides the closest thing to an unambiguous reference point, but its complexity keeps common names in circulation, and the growing volume of peptide research means the practical cost of that fragmentation continues to rise.
This article is intended for research and informational purposes only and does not constitute guidance for human use, diagnostic application, or therapeutic administration of any peptide compound.